Výsledky vyhledávání

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol

Autor: Michael Szarek, J. Wouter Jukema, Qian H Li, Harvey D. White, Investigators, Rafael Diaz, Deepak L. Bhatt, Robert Pordy, Shaun G. Goodman, Garen Manvelian, Timothée Sourdille, Gregory G. Schwartz, Philippe Gabriel Steg, Yong-Un Kim, Vera Bittner

Publikováno v: Circulation
Circulation, 143(11), 1109-1122. LIPPINCOTT WILLIAMS & WILKINS

Supplemental Digital Content is available in the text.
Background: Recent international guidelines have lowered recommended target levels of low-density lipoprotein cholesterol (LDL-C) for patients at very high risk for major adverse cardiovascu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fa80e828fa1ebae1157ae2e6a7d23ed
https://doi.org/10.1161/circulationaha.120.049447

Zobrazit plný text záznamu

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

Autor: Rafael Diaz, Michael Szarek, Christian Mueller, Shaun G. Goodman, Yong-Un Kim, J. Wouter Jukema, Odyssey Outcomes Investigators, José Tuñón, Andreas M. Zeiher, Gregory G. Schwartz, Philippe Gabriel Steg, Deepak L. Bhatt, Vera Bittner, Alexander Parkhomenko, Robert Pordy, Qian H Li, Harvey D. White, Piyamitr Sritara

Publikováno v: European Heart Journal
European Heart Journal, 41(42), 4114-4123. OXFORD UNIV PRESS
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Biblos-e Archivo. Repositorio Institucional de la UAM
instname

Aims Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb98ea40a69778d992ba5e422d5c18ee
http://europepmc.org/articles/PMC7700757

Zobrazit plný text záznamu

Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial

Autor: Robert A. Harrington, Vera Bittner, Harvey D. White, G G Schwartz, Michael Szarek, Joop Jukema, Rafael Diaz, Qian H Li, Deepak L. Bhatt, Andreas M. Zeiher, P G Steg, Yong-Un Kim, Shaun G. Goodman, Garen Manvelian

Publikováno v: European Heart Journal. 41

Background New ESC/EAS guidelines advise a low-density lipoprotein cholesterol (LDL-C) target level Aim To overcome these limitations, we performed a propensity score-matching (PSM) analysis of the ODYSSEY OUTCOMES trial, which compared the PCSK9 inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf99302dbdd5b41dc3b14af63361a179
https://doi.org/10.1093/ehjci/ehaa946.1736

Zobrazit plný text záznamu

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age

Publikováno v: European Heart Journal, 41(24), 2248-2258. OXFORD UNIV PRESS

Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients. Methods and results This prespecified analysis from ODYSSEY OUTCOMES compared the effect of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3eec6ae978e75bede6d63525db07e2
https://hdl.handle.net/1887/3232708

Zobrazit plný text záznamu

Peripheral artery disease and venous thromboembolic events after acute coronary syndrome role of lipoprotein(a) and modification aby alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial

Autor: Shaun G. Goodman, Gregory G. Schwartz, Harvey D. White, Matthew T. Roe, Philippe Gabriel Steg, Yong-Un Kim, Vera Bittner, Robert Pordy, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt, Investigators, Rafael Diaz

Publikováno v: Circulation, 141(20), 1608-1617. LIPPINCOTT WILLIAMS & WILKINS

Background: Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce lipoprotein(a) and low-density lipoprot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb4dc26897b3cbf01a5231029c87f38
http://hdl.handle.net/1887/3232577

Zobrazit plný text záznamu

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES

Autor: Gregory G. Schwartz, Philippe Gabriel Steg, Željko Reiner, Shaun G. Goodman, Pablo Carlos Montenegro Valdovinos, Robert Pordy, Vera Bittner, Harvey D. White, Andreas M. Zeiher, Laurien E Zijlstra, Michael Szarek, J. Wouter Jukema, Hung-Fat Tse, Matthew T. Roe, Rafael Diaz, Deepak L. Bhatt, Heinz Drexel, Yong-Un Kim

Publikováno v: Circulation, 140(25), 2054-2062. LIPPINCOTT WILLIAMS & WILKINS
Jukema, J Wouter; Zijlstra, Laurien E; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Drexel, Heinz; Goodman, Shaun G; Kim, Yong-Un; Pordy, Robert; Reiner, Zeljko; Roe, Matthew T; Tse, Hung Fat; Valdovinos, Pablo Carlos Montenegro; White, Harvey D; Zeiher, Andreas M; Szarek, Michael; Schwartz, Gregory G; Steg, Philippe Gabriel (2019). Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. Circulation, 140(25), pp. 2054-2062. American Heart Association 10.1161/CIRCULATIONAHA.119.043826
Circulation

Background: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be12a05ca96111cb0d2addf0c1aae229
https://doi.org/10.1161/circulationaha.119.043826

Zobrazit plný text záznamu

ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS

Autor: Terrance Chua, Johan Wouter Jukema, Vera Bittner, Robert Pordy, Gregory G. Schwartz, Shaun G. Goodman, H Asita de Silva, Harvey D. White, Matthew T. Roe, Maria Dorobantu, Deepak L. Bhatt, Rafael Diaz, Michael Szarek, Jennifer McGinniss, Andreas M. Zeiher, Philippe Gabriel Steg, Yong-Un Kim, Robert A. Harrington

Publikováno v: Journal of the American College of Cardiology. 75:1854

Statins reduce risk of major adverse cardiovascular events (MACE) in women and men; whether the same holds true for PCSK9 inhibition is uncertain. The ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or maximum-tolerat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db1e6102831a5749c80dc9ebc9cc7e6f
https://doi.org/10.1016/s0735-1097(20)32481-5

Zobrazit plný text záznamu

EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL

Autor: João Morais, Robert Pordy, Vera Bittner, Hyo-Soo Kim, Matthew T. Roe, Marco Valgimigli, Michael Szarek, Robert A. Harrington, Andreas M. Zeiher, Harvey D. White, Johan Wouter Jukema, Rafael Diaz, Nina Gotcheva, Deepak L. Bhatt, Gregory G. Schwartz, Shaun G. Goodman, Philippe Gabriel Steg, Yong-Un Kim, Chern-En Chiang

Publikováno v: Journal of the American College of Cardiology. 75:157

Background On urban roads, road users interact in a highly complex environment. Few previous multivariable studies investigated the association between the built urban environment (including the road, roadside and human activity) and crashes. Roadsid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::893fc1bb84ef8937e6782ef742c274d7
https://doi.org/10.1016/s0735-1097(20)30784-1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání